and NAFLD: Pathophysiology and Therapy

Overview

Journal Front Microbiol

Specialty Microbiology

Date 2024 Apr 4

PMID 38572244

Authors

Jun Zhang

Jing Zhou

Zheyun He

Hongshan Li

Affiliations

Soon will be listed here.

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a prevalent chronic liver condition observed globally, with the potential to progress to non-alcoholic steatohepatitis (NASH), cirrhosis, and even hepatocellular carcinoma. Currently, the US Food and Drug Administration (FDA) has not approved any drugs for the treatment of NAFLD. NAFLD is characterized by histopathological abnormalities in the liver, such as lipid accumulation, steatosis, hepatic balloon degeneration, and inflammation. Dysbiosis of the gut microbiota and its metabolites significantly contribute to the initiation and advancement of NAFLD. , a potential probiotic, has shown strong potential in preventing the onset and progression of NAFLD. However, the precise mechanism by which treats NAFLD remains uncertain. In this review, we explore the current understanding of the role of and its metabolites in the treatment of NAFLD, focusing on their ability to reduce liver inflammation, mitigate hepatic steatosis, and enhance intestinal barrier function. Additionally, we summarize how alleviates pathological changes by restoring the metabolism, improving insulin resistance, regulating cytokines, and promoting tight-junctions. A deeper comprehension of the mechanisms through which is involved in the pathogenesis of NAFLD should aid the development of innovative drugs targeting NAFLD.

Citing Articles

Naringenin cationic lipid-modified nanoparticles mitigate MASLD progression by modulating lipid homeostasis and gut microbiota.

Dong L, Lou W, Xu C, Wang J J Nanobiotechnology. 2025; 23(1):168.

PMID: 40038718 PMC: 11881431. DOI: 10.1186/s12951-025-03228-x.

From Dysbiosis to Hepatic Inflammation: A Narrative Review on the Diet-Microbiota-Liver Axis in Steatotic Liver Disease.

Pasta A, Formisano E, Calabrese F, Marabotto E, Furnari M, Bodini G Microorganisms. 2025; 13(2).

PMID: 40005608 PMC: 11857840. DOI: 10.3390/microorganisms13020241.

Microbial signatures in head and neck squamous cell carcinoma: an in silico study.

Kavitha L, Kuzhalmozhi M, Priyadharsini J, Arun Kumar A, Umadevi K, Ranganathan K J Appl Oral Sci. 2025; 33:e20240392.

PMID: 39907412 PMC: 11816647. DOI: 10.1590/1678-7757-2024-0392.

Next-Generation Probiotics and Chronic Diseases: A Review of Current Research and Future Directions.

Tiwari A, Krisnawati D, Susilowati E, Mutalik C, Kuo T J Agric Food Chem. 2024; 72(50):27679-27700.

PMID: 39588716 PMC: 11660543. DOI: 10.1021/acs.jafc.4c08702.

Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases.

Sandireddy R, Sakthivel S, Gupta P, Behari J, Tripathi M, Singh B Front Cell Dev Biol. 2024; 12:1433857.

PMID: 39086662 PMC: 11289778. DOI: 10.3389/fcell.2024.1433857.

References

Li Y, Yang Y, Wang J, Cai P, Li M, Tang X . Bacteroides ovatus-mediated CD27 MAIT cell activation is associated with obesity-related T2D progression. Cell Mol Immunol. 2022; 19(7):791-804. PMC: 9243016. DOI: 10.1038/s41423-022-00871-4. View

Rao A, Kosters A, Mells J, Zhang W, Setchell K, Amanso A . Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet-fed mice. Sci Transl Med. 2016; 8(357):357ra122. PMC: 5056562. DOI: 10.1126/scitranslmed.aaf4823. View

Zhang X, Ji X, Wang Q, Li J . New insight into inter-organ crosstalk contributing to the pathogenesis of non-alcoholic fatty liver disease (NAFLD). Protein Cell. 2017; 9(2):164-177. PMC: 5818366. DOI: 10.1007/s13238-017-0436-0. View

Horackova S, Plockova M, Demnerova K . Importance of microbial defence systems to bile salts and mechanisms of serum cholesterol reduction. Biotechnol Adv. 2017; 36(3):682-690. DOI: 10.1016/j.biotechadv.2017.12.005. View

Postic C, Dentin R, Denechaud P, Girard J . ChREBP, a transcriptional regulator of glucose and lipid metabolism. Annu Rev Nutr. 2007; 27:179-92. DOI: 10.1146/annurev.nutr.27.061406.093618. View

Li J, Chen Q, Yi J, Lan X, Lu K, Du X . IFN-γ contributes to the hepatic inflammation in HFD-induced nonalcoholic steatohepatitis by STAT1β/TLR2 signaling pathway. Mol Immunol. 2021; 134:118-128. DOI: 10.1016/j.molimm.2021.03.005. View

Li H, Wang S, Wang S, Yu H, Yu W, Ma X . Atorvastatin Inhibits High-Fat Diet-Induced Lipid Metabolism Disorders in Rats by Inhibiting Reduction and Improving Metabolism. Drug Des Devel Ther. 2022; 16:3805-3816. PMC: 9637332. DOI: 10.2147/DDDT.S379335. View

Chen Z, OShea J . Th17 cells: a new fate for differentiating helper T cells. Immunol Res. 2008; 41(2):87-102. DOI: 10.1007/s12026-007-8014-9. View

Jiao N, Baker S, Chapa-Rodriguez A, Liu W, Nugent C, Tsompana M . Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD. Gut. 2017; 67(10):1881-1891. DOI: 10.1136/gutjnl-2017-314307. View

10.

Cani P, de Vos W . Next-Generation Beneficial Microbes: The Case of . Front Microbiol. 2017; 8:1765. PMC: 5614963. DOI: 10.3389/fmicb.2017.01765. View

11.

Mantovani A, Dalbeni A . Treatments for NAFLD: State of Art. Int J Mol Sci. 2021; 22(5). PMC: 7956331. DOI: 10.3390/ijms22052350. View

12.

Younossi Z, Golabi P, Paik J, Henry A, Van Dongen C, Henry L . The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023; 77(4):1335-1347. PMC: 10026948. DOI: 10.1097/HEP.0000000000000004. View

13.

Geerts A, Lefere S . Bariatric surgery for non-alcoholic fatty liver disease: Indications and post-operative management. Clin Mol Hepatol. 2022; 29(Suppl):S276-S285. PMC: 10029945. DOI: 10.3350/cmh.2022.0373. View

14.

Arellano-Garcia L, Trepiana J, Martinez J, Portillo M, Milton-Laskibar I . Beneficial Effects of Viable and Heat-Inactivated GG Administration on Oxidative Stress and Inflammation in Diet-Induced NAFLD in Rats. Antioxidants (Basel). 2023; 12(3). PMC: 10045382. DOI: 10.3390/antiox12030717. View

15.

Gao Q, Jia Y, Yang G, Zhang X, Boddu P, Petersen B . PPARα-Deficient ob/ob Obese Mice Become More Obese and Manifest Severe Hepatic Steatosis Due to Decreased Fatty Acid Oxidation. Am J Pathol. 2015; 185(5):1396-408. PMC: 4419205. DOI: 10.1016/j.ajpath.2015.01.018. View

16.

Jin C, Engstler A, Sellmann C, Ziegenhardt D, Landmann M, Kanuri G . Sodium butyrate protects mice from the development of the early signs of non-alcoholic fatty liver disease: role of melatonin and lipid peroxidation. Br J Nutr. 2016; 116(10):1682-1693. DOI: 10.1017/S0007114516004025. View

17.

Turnbaugh P, Ley R, Mahowald M, Magrini V, Mardis E, Gordon J . An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006; 444(7122):1027-31. DOI: 10.1038/nature05414. View

18.

Da Silva H, Teterina A, Comelli E, Taibi A, Arendt B, Fischer S . Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance. Sci Rep. 2018; 8(1):1466. PMC: 5780381. DOI: 10.1038/s41598-018-19753-9. View

19.

Zhou C, Wang Y, Li C, Xie Z, Dai L . Amelioration of Colitis by a Gut Bacterial Consortium Producing Anti-Inflammatory Secondary Bile Acids. Microbiol Spectr. 2023; :e0333022. PMC: 10101101. DOI: 10.1128/spectrum.03330-22. View

20.

Maestri M, Santopaolo F, Pompili M, Gasbarrini A, Ponziani F . Gut microbiota modulation in patients with non-alcoholic fatty liver disease: Effects of current treatments and future strategies. Front Nutr. 2023; 10:1110536. PMC: 9978194. DOI: 10.3389/fnut.2023.1110536. View